Summary
Dr Sofia Pappa is a Senior Lecturer at the Division of Psychiatry, Imperial College London and a Specialty Lead in Mental Health for the National Institute for Health Research (NIHR,UK). She also works as a Consultant Psychiatrist and Mood & Psychosis Research Lead at West London NHS Trust.
She has dual training in Neurology and Psychiatry and was awarded a European scholarship for the completion of her PhD. She subsequently obtained a fellowship for postdoctoral research at the Institute of Psychiatry, Kings College London, evaluating the neuromotor dysfunction in early psychosis.
Her main clinical and research interests include neuropsychopharmacology and novel treatments in the management of affective and psychotic disorders. She has also a keen interest in the interface between physical and mental health, neuropsychiatry (particularly in movement and sleep disorders) and patient involvement.
Dr Pappa has received a number of awards and grants and has acted as Principal Investigator for several clinical trials. She has published in high impact journals and regularly reviews manuscripts for top ranked journals and NIHR applications.
She has significant experience in teaching including in her role as Imperial Medical School Tutor and Associate Clinical Professor in Psychiatry, RUSM Medical School (Florida, US) and in clinical management, having served as Clinical Lead for Adult Mental Health Services in the past.
Publications
Journals
King JD, Cheng S, Fok ML-Y, et al. , 2023, Interventions to improve the sleep quality of adults with personality disorder: a systematic review, Personality and Mental Health: Multidisciplinary Studies From Personality Dysfunction to Criminal Behaviour, ISSN:1932-8621
Pappa S, Kalniunas A, Maret J, 2023, Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up, Frontiers in Psychiatry, Vol:14, ISSN:1664-0640, Pages:1-5
Puntis S, Pappa S, Lennox B, 2023, What happens after early intervention? Mapping early intervention in psychosis care pathways in the 12 months after discharge., Early Interv Psychiatry
Winter-van Rossum I, Weiser M, Galderisi S, et al. , 2023, Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)., Lancet Psychiatry, Vol:10, Pages:197-208
Pappa S, Barnett J, Mason K, 2023, A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone Palmitate: implications for clinical decision making, Cns Drugs, Vol:37, ISSN:1172-7047, Pages:107-116